Wahlgren C-M, Swedenborg J
Department of Vascular Surgery, Karolinska Hospital, 171 76 Stockholm, Sweden.
Eur J Vasc Endovasc Surg. 2003 Aug;26(2):221-2. doi: 10.1053/ejvs.2002.1887.
Recombinant activated factor VII (rFVIIa) was first used to control bleeding in haemophilia patients. More recently, it has been used to prevent severe bleeding in patients without pre-existing coagulopathy. We report a case where rFVIIa was used to successfully control postoperative bleeding in a patient undergoing suprarenal abdominal aortic aneurysm (AAA) repair.
重组活化凝血因子VII（rFVIIa）最初用于控制血友病患者的出血。最近，它已被用于预防无既往凝血功能障碍患者的严重出血。我们报告了一例在接受肾上腺腹主动脉瘤（AAA）修复手术的患者中使用rFVIIa成功控制术后出血的病例。
